NCT06777810

Brief Summary

The objective of this study is to design and develop a gene chip for detecting pathogenic bacteria in diabetic foot infection wounds. This innovative gene chip technology enables rapid and accurate identification of pathogens at the site of infection by detecting the 16SrDNA sequence of pathogenic bacteria. Diabetic foot infection is a common serious complication in diabetic patients, often accompanied by complex pathogenic bacteria population, and due to the variety of infection types, traditional pathogen detection methods are time-consuming and low accuracy, patients may miss the best treatment opportunity. Now commonly used genetic identification of pathogenic bacteria often find a variety of bacteria, resulting in the actual pathogenic bacteria difficult to judge.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2025

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 10, 2024

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 16, 2025

Completed
15 days until next milestone

Study Start

First participant enrolled

January 31, 2025

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2026

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2026

Completed
Last Updated

January 16, 2025

Status Verified

November 1, 2024

Enrollment Period

1 year

First QC Date

December 10, 2024

Last Update Submit

January 10, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Diagnostic accuracy of gene chips:Sensitivity, Specificity, Positive Predictive Value (PPV), NegativePredictive Value (NPV)

    through study completion, an average of 1 year

  • The time (in minutes) taken for diagnosis using the gene chip method compared to the traditional method.

    through study completion, an average of 1 year

Secondary Outcomes (1)

  • The time (in days) required for ulcer healing using the gene chip method compared to the traditional method.

    through study completion, an average of 1 year

Interventions

The infected wound of the patient's foot ulcer was collected

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Diabetic foot infection patients

You may qualify if:

  • Age ≥ 18 years old
  • Gender: males and females
  • Patients diagnosed with diabetic foot infection with an infected wound
  • It can provide sufficient infected wound samples (≥5mm³ infected wound tissue samples or ≥100μL infected wound secretions) and can be used for detection and analysis of gene chips
  • No history of antibiotic therapy prior to sampling (within 4 weeks) or known failure to respond to antibiotic therapy (failure to respond to ≥2 antibiotics)
  • Fully understand the nature, significance, possible benefits, possible inconveniences or potential risks of this research; Understand the study procedure, participate voluntarily and be willing to complete the entire study process, and sign the informed consent

You may not qualify if:

  • Patients with undiagnosed diabetic foot infection
  • Patients who had received antibiotics within 4 weeks prior to sampling
  • Complicated with serious systemic disease (e.g., malignant tumor, severe cardiopulmonary insufficiency, etc.)
  • Pregnant or lactating women
  • Cognitive impairment or inability to cooperate with the research process
  • History of allergies or allergies to materials related to the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Clinical Medical Research Center for Metabolic Diseases (Shanghai)

Shanghai, China

Location

MeSH Terms

Conditions

Diabetic FootDiabetes Mellitus

Condition Hierarchy (Ancestors)

Diabetic AngiopathiesVascular DiseasesCardiovascular DiseasesFoot UlcerLeg UlcerSkin UlcerSkin DiseasesSkin and Connective Tissue DiseasesDiabetes ComplicationsEndocrine System DiseasesDiabetic NeuropathiesGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Central Study Contacts

Weiqing Wang, MD, PHD

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
OTHER
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

December 10, 2024

First Posted

January 16, 2025

Study Start

January 31, 2025

Primary Completion

January 31, 2026

Study Completion

June 30, 2026

Last Updated

January 16, 2025

Record last verified: 2024-11

Locations